Provided is a novel material used to introduce an exogenous substance into cells. Also provided is a method for introducing an exogenous substance into target cells using this material. The present invention provides an exosome that is used to introduce an exogenous substance into target cells, wherein the exosome contains one type or two or more types of an exogenous substance and a substance that induces macropinocytosis in the target cells. The present invention also provides a composition containing the exosome and a method for introducing an exogenous substance into cells using this exosome.

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration. Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

The invention relates to the technical field of traditional Chinese medicine, and discloses a method of traditional Chinese medicine and microcapsule preparation suitable for nasopharyngeal cancer tumor inhibitors. A traditional Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors, including: Hedyotis Diffusa, Scutellaria Barbata, Arrowshaped Tinospora Root, Rehmanniae Radix Preparata, Radix Curcumae, Crotonis Fructus, Leonurus Artemisia, Ramulus Cinnamomi, Forsythiae Fructus, Taraxacum, Radix Platycodonis and White Vinegar. Among them, the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa, 30 grams of Scutellaria Barbata, 9-12 grams of Arrowshaped Tinospora Root, 18 grams of Rehmanniae Radix Preparata, 19 grams of Radix Curcumae, 7.5 grams of Crotonis Fructus, 10 grams of Leonurus Artemisia, 7-10 grams of Ramulus Cinnamomi, 10 grams of Forsythiae Fructus, 15-30 grams of Taraxacum, 10 g of Radix Platycodonis, and 30 ml of White Vinegar.

Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.

Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

A method of preparing water-soluble lutein ester microcapsules includes: mixing marigold flower particles with an extracting solvent, refluxing at 65-85° C.; removing the extracting solvent to obtain a crude extract; washing the crude extract with a washing solvent; removing the washing solvent to obtain a crude lutein ester; adding an oil-phase antioxidant and a vegetable oil to the crude lutein ester, mixing and heating at 90-100° C. to obtain a lutein ester oil phase; adding a wall material, an emulsifier, a water-phase antioxidant, and a water-phase filler into water, and heating to obtain a water phase; adding the lutein ester oil phase to the water phase under a high-speed shearing, mixing evenly, and homogenizing to obtain a lutein ester emulsion; drying twice to obtain semi-finished lutein ester microcapsules; and solidifying to obtain the lutein ester microcapsules. Water-soluble lutein ester microcapsules prepared by the method are also disclosed.

Disclosed is a lipid composition including, per 100% of its weight:—from 40% to 99.9% by weight of a component including, per 100% of its weight, from 90% to 100% by weight of beeswax and up to 10% by weight of at least one other lipid excipient,—from 0.1% to 60% by weight of at least one lipophilic surfactant.

The present invention relates to a method for subjecting a subject to an augmented reality (AR) or virtual reality (VR) experience. The method may comprise administering to the subject a composition comprising a cannabinoid compound. The method may comprise, subsequent to the administration of the composition comprising the cannabinoid compound, using an AR or VR device to subject the subject to an AR or VR experience. The method may comprise detecting a response of the subject to the AR or VR experience and the composition comprising the cannabinoid compound.

The present invention relates to a method for preparing a granule or a pill containing a plant, medicinal herb or traditional oriental medicine decoction extract, having the steps of: (a) injecting a powdered plant, medicinal herb or traditional oriental medicine decoction extract into a fluidized-bed device and spraying purified water or a solution of the same type of extract as the extract powder at the extract powder while fluidizing the same, thereby generating microgranules of the extract powder; and (b) injecting the microgranules generated at step (a) as seeds into the fluidized-bed device and spraying a solution of the extract while fluidizing the same, thereby growing the microgranules to a predetermined size of granule or pill. According to the present invention, it is possible to prepare a granule or a pill containing an extract in a high concentration.

The present invention relates to a new delivery system for PUFAs.